Gilead Sciences – Talk Bio

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

2 weeks ago talkbio0Tagged Appointments, Atacicept, Autoimmune Diseases, Biological Factors, biotech executive, board of directors, Gilead Sciences, IGA Glomerulonephritis, IntraBio Ltd., James, Vera Therapeutics

Vera Therapeutics; James R. Meyers; Board of Directors; appointment; biotech executive; IgA nephropathy; atacicept; autoimmune diseases; Gilead Sciences; IntraBio Ltd; biopharmaceutical

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

1 month ago talkbio0Tagged Biktarvy, cell therapy sales, financial results, Gilead Sciences, HIV franchise, Livdelzi, Q3, Tecartus, Trodelvy, Veklury, Yescarta, Yeztugo

Gilead Sciences; cell therapy sales; Q3 2025 financial results; HIV franchise; Yescarta; Tecartus; Biktarvy; Yeztugo; Livdelzi; Trodelvy; Veklury

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

3 months ago talkbio0Tagged Billion, Biological Factors, California, economic impact, expansion, Foster City, Gilead Sciences, Investments, Manufacturing, Manufacturing Facilities, R&D, Surgical construction, United States

Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing

Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares

4 months ago talkbio0Tagged ABI-5366, Assembly (construction), Bio, Collaboration, genital lesion reduction, Gilead Sciences, herpesvirus 2, human, safety profile, Simplexvirus, stock purchase, viral shedding

Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

5 months ago talkbio0Tagged Business Development, Cell Therapy, Galapagos, Gilead Sciences, GLPG5101, Mantle cell lymphoma, pipeline, Sales - occupational activity, strategic alternatives

Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

6 months ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot

6 months ago talkbio0Tagged Approved, Gilead Sciences, HIV Prevention, Lenacapavir, PREP gene, public health medicine (field), twice-yearly injection, United States Food and Drug Administration, Yeztugo

FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health

Gilead Lays Off 36 Employees After Cancelling Oceanside, California Expansion

6 months ago talkbio0Tagged Biological Factors, biotech industry, California, co-location, expansion, Facility (object), Foster City, Gilead Sciences, layoffs, Oceanside

Gilead Sciences; layoffs; Oceanside; California; biologics; facility expansion; job cuts; biotech industry; co-location; Foster City

FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns

6 months ago talkbio0Tagged Biktarvy, CD4 + T-cell, Clinical Trials, Gilead Sciences, GS-1720, GS-4182, HIV, Lenacapavir, Lymphocyte Count measurement, safety signal, Study on Hold, United States Food and Drug Administration

FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

6 months ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy